Full text

Turn on search term navigation

© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Acyclovir has a short half-life and offers poor bioavailability. Its daily dose is 200 mg five times a day. A tamarind gum and β-cyclodextrin-based pH-responsive hydrogel network for sustained delivery of acyclovir was developed using the free-radical polymerization technique. Developed networks were characterized by FTIR, DSC, TGA, PXRD, EDX, and SEM. The effect of varying feed ratios of polymers, monomers, and crosslinker on the gel fraction, swelling, and release was also investigated. FTIR findings confirmed the compatibility of the ingredients in a new complex polymer. The thermal stability of acyclovir was increased within the newly synthesized polymer. SEM photomicrographs confirmed the porous texture of hydrogels. The gel fraction was improved (from 90.12% to 98.12%) with increased reactant concentrations. The pH of the dissolution medium and the reactant contents affected swelling dynamics and acyclovir release from the developed carrier system. Based on the R2 value, the best-fit model was zero-order kinetics with non-Fickian diffusion as a release mechanism. The biocompatibility of the developed network was confirmed through hematology, LFT, RFT, lipid profile, and histopathological examinations. No sign of pathology, necrosis, or abrasion was observed. Thus, a pH-responsive and biocompatible polymeric system was developed for sustained delivery of acyclovir to reduce the dosing frequency and improve patient compliance.

Details

Title
Development and Optimization of Tamarind Gum-β-Cyclodextrin-g-Poly(Methacrylate) pH-Responsive Hydrogels for Sustained Delivery of Acyclovir
Author
Kanza Shafiq 1 ; Mahmood, Asif 2   VIAFID ORCID Logo  ; Salem-Bekhit, Mounir M 3   VIAFID ORCID Logo  ; Rai, Muhammad Sarfraz 4   VIAFID ORCID Logo  ; Algarni, Alanood S 5   VIAFID ORCID Logo  ; Taha, Ehab I 3   VIAFID ORCID Logo  ; Mansour, Ahd A 6   VIAFID ORCID Logo  ; Sami Al Zahrani 7 ; Benguerba, Yacine 8 

 Faculty of Pharmacy, The University of Lahore, Lahore 54000, Pakistan 
 Faculty of Pharmacy, The University of Lahore, Lahore 54000, Pakistan; Department of Pharmacy, University of Chakwal, Chakwal 48800, Pakistan 
 Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 12234, Saudi Arabia 
 College of Pharmacy, University of Sargodha, Sargodha 40100, Pakistan 
 Department of Pharmacology and Toxicology, Faculty of Pharmacy, Pharmacy Collage, Umm Al-Qura University, Makkah 21955, Saudi Arabia 
 Medical Laboratory Science Department, Fakeeh College for Medical Sciences, Jeddah 21461, Saudi Arabia 
 Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 12234, Saudi Arabia; Pharmaceutical Care Department, National Guard Health Affairs, Riyadh 11426, Saudi Arabia 
 Laboratoire de Biopharmacie Et Pharmacotechnie (LBPT), Ferhat Abbas Setif 1 University, Setif 19000, Algeria 
First page
1527
Publication year
2022
Publication date
2022
Publisher
MDPI AG
e-ISSN
14248247
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2756774639
Copyright
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.